Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.24. Operator: Welcome to the Rani ...

Welcome to the Rani Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following management's ...

At Rani Therapeutics, Our mission is to end painful injections ... significantly higher dose than its subcutaneous counterpart. In contrast, the target product profile of semaglutide in the ...

Ozempic (semaglutide ... occur in people using Ozempic or Victoza. In general, serious side effects from these drugs are rare. The following chart lists the possible serious side effect of ...

Ozempic (semaglutide) is prescribed for adults with type 2 diabetes. The drug is given as an injection ... The maximum dose for Ozempic is 2 mg once per week. The following dosing chart shows ...

Unlike newer GLP-1 entrants, Liraglutide’s established track record and daily dosing format offer flexibility ... Delivered via once-daily injection, it offers consistent and clinically proven ...

It announced it would make GLP-1 injections available ... ingredients, purity, dosage accuracy and efficacy. HIMS and the industry in general, will need to be vigilant about quality control.

Mounjaro, a once-weekly injection approved by India’s drug regulator ... the company told Reuters exclusively. Its highest dose is 15 mg. A patient in India may have to spend about $200 a ...

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key ...

The high plasma concentrations with prolonged systemic exposure were consistent with the reported half-life for semaglutide (Rybelsus ... single dose pharmacokinetic study in rodents.